Robins Harlan S's Form 4 filing

Adaptive Biotechnologies Corp (ADPT) · filed Mar 4, 2026

Accession no.: 0001780851-26-000003
Filed: Mar 4, 2026
Trade date: Mar 2-3, 2026
Filing delay: 2 days
Rule 10b5-1 plan: Checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $392.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Robins Harlan SCIK 0001780851	Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Mar 2, 2026	Common Stock	SSaleDisposed	−10,000	$15.72^F2	−$157,200	1,169,524	Direct
Mar 3, 2026	Common Stock	SSaleDisposed	−14,233	$16.52^F3	−$235,129.16	1,155,291	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.57 to $15.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Referenced by the price of 1 transaction in Table I.

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)